The FDA’s Accelerated Approval Program allows for the earlier approval of drugs to fill an unmet clinical need, according to the agency’s website.
The agency approved the drug, Lartruvo, for combined use with the chemotherapy agent doxorubicin in soft tissue sarcoma patients who cannot be cured with radiation or surgery, according to the report.
Lartruvo earned orphan drug status and breakthrough therapy status — designations intended to expedite the development and review of promising new drugs — from the FDA prior to winning accelerated approval.
More articles on supply chain:
FDA OKs Roche’s Tecentriq for lung cancer patients
Texas Medical Center partners with J&J to develop medical devices
Prescription drug costs see largest jump in 24 years
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
